BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...CD135) - FMS-like tyrosine kinase 3 BC Staff NIH 89bio Takeda Nestle S.A. AIMM...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...developing small molecule inhibitors of an undisclosed RNA-binding protein to treat amyotrophic lateral sclerosis (ALS). AIMM...
...Fund, Osage University Partners, Sofinnova Partners CEO: Kazumi Shiosaki Patents: None Companies and Institutions Mentioned AIMM...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...with immunotherapies for therapeutic antibodies, and the first to disclose the targets it has found. AIMM...
...and has Breakthrough designation from FDA and Prime designation from EMA. John Womelsdorf, who became AIMM’s...
...in remission for six years following treatment with an early form of T cell immunotherapy. AIMM...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

...cells; an antibody to the epitope eliminated AML cells in vivo Academic Medical Center ; AIMM...
BioCentury | Mar 7, 2017
Company News

AZ, Sanofi deal

...are mAbs that bind the RSV F protein . MedImmune holds rights to MEDI8897 from AIMM...
BioCentury | Mar 3, 2017
Company News

AZ, Sanofi sharing rights to infant RSV prophylaxis

...are mAbs that bind the RSV F protein . MedImmune holds rights to MEDI8897 from AIMM...
BioCentury | Apr 20, 2015
Clinical News

RSV mAb regulatory update

...Ib/IIa testing in healthy preterm infants. MedImmune has rights to develop the product from AIMM. AIMM...
BioCentury | Jan 8, 2015
Distillery Techniques

Techniques: Fused bispecific antibodies

...al. Proc. Natl. Acad. Sci. USA; published online Nov. 10, 2014 doi:10.1073/pnas.1408605111 CONTACT: Hergen Spits, AIMM...
BioCentury | Dec 9, 2013
Clinical News

Allovectin velimogene aliplasmid: Additional Phase III data

...Additional data from the single-blind, international Phase III AIMM trial in 390 chemotherapy-naïve patients with recurrent...
...Research meeting in Philadelphia. In August, Vical discontinued development of Allovectin after top-line data from AIMM...
BioCentury | Nov 14, 2013
Targets & Mechanisms

RSVing for site zero

...a team from the NIH and China identified 5C4 and another team from antibody company AIMM...
...Baas, T. SciBX 6 (44); doi:10.1038/scibx.2013.1247 Published online Nov. 14, 2013 Companies and Institutions Mentioned AIMM...
Items per page:
1 - 10 of 113
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...CD135) - FMS-like tyrosine kinase 3 BC Staff NIH 89bio Takeda Nestle S.A. AIMM...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...developing small molecule inhibitors of an undisclosed RNA-binding protein to treat amyotrophic lateral sclerosis (ALS). AIMM...
...Fund, Osage University Partners, Sofinnova Partners CEO: Kazumi Shiosaki Patents: None Companies and Institutions Mentioned AIMM...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...with immunotherapies for therapeutic antibodies, and the first to disclose the targets it has found. AIMM...
...and has Breakthrough designation from FDA and Prime designation from EMA. John Womelsdorf, who became AIMM’s...
...in remission for six years following treatment with an early form of T cell immunotherapy. AIMM...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

...cells; an antibody to the epitope eliminated AML cells in vivo Academic Medical Center ; AIMM...
BioCentury | Mar 7, 2017
Company News

AZ, Sanofi deal

...are mAbs that bind the RSV F protein . MedImmune holds rights to MEDI8897 from AIMM...
BioCentury | Mar 3, 2017
Company News

AZ, Sanofi sharing rights to infant RSV prophylaxis

...are mAbs that bind the RSV F protein . MedImmune holds rights to MEDI8897 from AIMM...
BioCentury | Apr 20, 2015
Clinical News

RSV mAb regulatory update

...Ib/IIa testing in healthy preterm infants. MedImmune has rights to develop the product from AIMM. AIMM...
BioCentury | Jan 8, 2015
Distillery Techniques

Techniques: Fused bispecific antibodies

...al. Proc. Natl. Acad. Sci. USA; published online Nov. 10, 2014 doi:10.1073/pnas.1408605111 CONTACT: Hergen Spits, AIMM...
BioCentury | Dec 9, 2013
Clinical News

Allovectin velimogene aliplasmid: Additional Phase III data

...Additional data from the single-blind, international Phase III AIMM trial in 390 chemotherapy-naïve patients with recurrent...
...Research meeting in Philadelphia. In August, Vical discontinued development of Allovectin after top-line data from AIMM...
BioCentury | Nov 14, 2013
Targets & Mechanisms

RSVing for site zero

...a team from the NIH and China identified 5C4 and another team from antibody company AIMM...
...Baas, T. SciBX 6 (44); doi:10.1038/scibx.2013.1247 Published online Nov. 14, 2013 Companies and Institutions Mentioned AIMM...
Items per page:
1 - 10 of 113